Gamaleya Center to test nasal coronavirus vaccine

The Ministry of Health issued the Gamaleya Center permission to conduct phases I-II clinical trials of a vaccine against COVID-19 based on virus-like particles (VLP), follows from the register of approved clinical trials of the ministry. The vaccine is being developed in a nasal form. In February, the agency issued permission to study the same Gamaleya Center vaccine in the form of an injection.

“The purpose of the clinical study: to evaluate the tolerability, safety and immunogenicity of the VLP-based vaccine for the prevention of COVID-19 when administered intranasally in volunteers aged 18–55 years,” follows from the registry.

It is reported that 600 people will take part in the vaccine study. Clinical trials will take place on the basis of six institutions in St. Petersburg, Kirov, Moscow, Novosibirsk and Moscow regions. Tests will be held from August 31 to December 30.

Formerly Gamaleya Center informed on the development of a new version of the Sputnik V vaccine adapted to the delta and omicron coronavirus strains. Head of the organization Alexander Gintsburg told on the creation of the subvalent platform “Sputnik V” against three new types of “omicron” (BA.1, BA.2, BA.5). Mr Gunzburg expects increase in incidence to the levels of last winter.

According to the operational headquarters, 46,321 cases of coronavirus infection were detected in Russia over the past day. The day before, on August 30, 37,067 cases of the disease were registered in the country. Rospotrebnadzor does not plan to introduce restrictive measures. Against the backdrop of a growing incidence, the recommended mask regimen introduced in six regions of the country. WHO expects new outbreak of COVID-19 in Europe in the fall.

Earlier, Kommersant reported that the first nasal vaccines launched in the Kursk region turned out to be the usual Sputnik V. It was noted that almost 7 thousand people were vaccinated with the nasal vaccine in the region. Experts noted the medical and legal groundlessness of using such a vaccine.

More about nasal vaccines – in the publication “Kommersant” “COVID is left with a nose”

Lusine Balasyan